Company intelligence / Profile preview
Aprogen Biologics Inc.
Seongnam-si, South Koreaaprogen.com ↗
- Ownership
- Private
- Employees
- ~377
- Development stage
- Other
01
Overview
The company has multiple biosimilars in development with one at NDA/BLA stage (Rituximab biosimilar) and one in Phase 1 (Adalimumab biosimilar). They also have approved products including Azelaic Acid for acne vulgaris.
- Therapeutic areas
- OncologyDermatologyRheumatologyImmunology
- Modalities
- Monoclonal antibodiesBispecific antibodiesBiosimilarsSmall molecule drugsFc Fragment
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Nichi-Iko Pharmaceuticals Co. Ltd. (Japan)
Beyond the preview
Go deeper on Aprogen Biologics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aprogen Biologics Inc..